Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  2.00 1.04% 195.00 2,960,986 16:35:04
Bid Price Offer Price High Price Low Price Open Price
192.00 196.00 202.50 187.75 188.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.51 -18.05 -12.98 494
Last Trade Time Trade Type Trade Size Trade Price Currency
17:56:36 O 10,000 196.35 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Investors    Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-02-26 17:58:38196.3510,00019,635.00O
2021-02-26 17:27:33193.167,08713,688.93O
2021-02-26 17:21:04194.4510,28519,999.18O
2021-02-26 17:16:17192.009,23817,736.96O
2021-02-26 17:15:00195.0045,06387,872.85O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
27/2/2021
08:20
Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 193p.
Avacta Group Plc has a 4 week average price of 121.50p and a 12 week average price of 104p.
The 1 year high share price is 222.50p while the 1 year low share price is currently 13.50p.
There are currently 253,236,345 shares in issue and the average daily traded volume is 5,662,500 shares. The market capitalisation of Avacta Group Plc is £493,810,872.75.
25/2/2021
17:31
lukead: 1) i don't know about age profile of India, but that is cerainly a low death rate in India. Maybe their diet is better, maybe obesity is not so much of a problem 2) litho says that is his last post on advfn, in a way, you can not blame him, what with the scumbags that turn up and ADVFN just let let them get on with it, having said that, i have not seen the dreaded "king" lately, touchwood. 3) the share price finished, if not at an all time high, must be close to it, disregarding inter day highs. That is very encouraging. 4) The interview was first class, AS was very self assured and confident and at ease with the interviewer. A guy at the top of his game. (just with the added rider, that remember, he is paid to sell the company and it would be foolish to get too carried away with events). Notwithstanding, AVCT is showing every sign of at last having the makings of it being made into a monumental company. Now only weeks away from the very start of it's commercial phase, with the orders set to roll in for its rapid test kits. And hopefully, the revenue produced will pay for the cancer treatments, which according to Myles, will be the real life game changer. (the test kits, being the appetiser). No need for further cash calls/dilution Lets hope there are no hitches and that the sale of these test kits do become the start of its commercial thrust. PS, i think Litho will be back, ive got a pound on it.
25/2/2021
12:33
lithological heterogeneities: Just one final post. What a great interviewer. Very enthusiastic and knowledgeable. Loved his comparisons with other companies worth over $20 billion each and Avacta looks bigger ! $20 billion = £14 billion. Avacta now 0.45 billion. So for AVCT to reach that figure the mkt cap would have to go up 31x . So share price could go up 31x from here over the years. Thats 31x £1.90 = £58.90 share price. And as he said one of the companies is currently $27 billion. $27 billion = £19.3 billion . £19.3 billion ÷ £0.45 billion = 43x. 43 × £1.90 = £81.50 share price. And Avacta are in several multi billion markets so could be bigger ! It seems utterly absurd I know, but on a direct comparison with the $20-$27 billion companies it is 100% accurate,especially when we list on Nasdaq which "Sir Al" has already said is part of the plan going forward. My favourite part of the interview was that first dosing is in middle of year and first results by end of year. He has already spoken to the regulatory authorities who say that because Doxorubicin cancer drug has been well studied for 40 years they will get accelerated Approvals for Phase 2 and will not even need to go into the very long Phase 3. Then he mentioned several others already lined up to go through the same process ! In addition to covid and massive stem cell therapy market and loads of other incredible therapies. Could be one one of the biggest companies in the World imho. That's my last post on AVCT BB. No point reading anymore. Just buy and retire. Good luck.
24/2/2021
22:19
lukead: ·HERE ARE SOME MM'S THOUGHTS ON TODAYS TU, AS YOU WILL SEE HE TOUCHES ON THE PROFESSIONAL VS HOME USE QUESTION. HE IS STILL ULTRA BULLISH THAT THIS SHARE WILL EXPLODE INTO MULTIPLE OF CURRENT VALUE. HE SAYS HE ADDED TO HIS ALEADY VAST HOLDING TODAY AT 172P........... Pricing? 6 pounds for Governments, IMO; £10-12 for Corporates. I think at £6, AVCT will be looking at a PBT of £1.50 per unit Two standout comments: "Healthcare services providers and governments are likely to be the largest volume customers." AVCT "expects demand to be present for rapid testing for at least two years and probably for longer." A standout ambiguity is again the detail (or rather, lack thereof) on current manufacturing capacity. "Several million per month." BBI, ABDX and GAD can each produce more than several million pm, as it stands. Evidently however, there are already further undisclosed... ...agreements in place: The collaboration with Mologic also provides manufacturing capacity... with GAD in addition to the agreements with BBI Group, Abingdon Health AND OTHERS..." And: AVCT is continuing its discussions with other manufacturers in the UK and overseas." I think it is obvious that the "several million per month" figure does not stack up; and if not already, will be surpassed (by many multiples, IMO) very quickly. Another interesting point: the disclaimer that began appearing in #AVCT's RNSs last week: "Disclaimer: AffiDx SARS-CoV-2 Lateral Flow Rapid Antigen Test not currently for sale in the US." A precursor to applying for FDA approval perhaps? It is possible that a CE Marking would fast-track this process. The US would clearly be a tremendous market for the product. To my surprise, there was no mention of the lay user study. I imagine that AVCT is focussing on getting the LFT to market in the fastest way possible first - professional use only CE Mark - and only after that will it launch the lay user study. However, that study is......critical for AVCT to establish its dominance over the global LFT market, and secure the longer-term revenues. Perhaps it is waiting for the mologic/avacta hybrid super LFT to be finalised, before attempting to nail the at-home market? UK and RoW vaccine passports. This could well become a thing, a la Yellow Fever certificates for some countries. However, the backlash against this is already evident. The obvious solution, and one which I think will materialise shortly, is the vaccine AND/OR LFT passport. Several potential candidates could enter clinic next year. The first Affimer-based therapeutic will almost certainly do so - my hope is that AVCT will jump straight into the clinic with TMAC, and not wait for Affimer safety data from a bispecific trial first. Summary: avacta appears very likely to launch the most accurate COVID19 LFT in the world in a few weeks' time. It seems highly likely that the Co will never be forced to raise equity again on the public markets. The cash generated will be used to fast-track the...development of its three proprietary therapeutic platforms (not drugs; but distinct platforms) - each which could ultimately achieve dizzying price tags. There remains very large risk in the Therapeutics division; but now limited risk in the Diagnostics division. The latter - singlehandedly - could shortly drive AVCT's share price to multiples of its current level, as the power of Affimers becomes acknowledged by the global diagnostics industry (and of course, as avacta starts printing cash!). All my opinion, and as a biased holder
21/2/2021
21:59
fictitious1: Lukead, I am pretty confident the share price will be past 200p early doors based on the positive media coverage. If you think that news warrants an rns, fair enough. But we've been told (rns'd) the test works, tested in couple of places. If the Porton Down 'leak' intimates more, then not only I'd expect an rns, some serious questions should be asked within PD about the info if AVCT had been kept silenced by an apparent NDA. ps., I wished peeps wouldn't just down tick a post without contributing an alternative view. I'd welcome all opinions, but to hide behind a keyboard down ticking is poor show imo. Don't post much but am a holder. Happy to keep my thoughts within! GL. PS., another poor show by Spurs! :0(
21/2/2021
07:46
rivaldo: Impossible to know whether AVCT will release anything tomorrow morning. I suspect if anything is released it may be during the day, in response (hopefully!) to the large share price rise following the Huff Post article, noting Boris's press conference to come and revealing as much as they can prior to his speech. Unless there's definitive news from Porton Down or otherwise which AVCT are entitled to RNS of course, as boysie72 says, which is what the RNS system in meant for. I've switched to this thread too to escape the lunatics :o))
19/2/2021
20:09
lithological heterogeneities: Brilliant newsAs I thought we would be, we are in the second phase from April.And Mologic will manufacture our test Worldwide and,as we own 100% of the Worldwide rights on affimers, it will open the doors to every government in the World to place orders and all we have to do is sell them the strips & affimers and they pay for the manufacturing costs themselves.Then we have the Gold Standard BAMS PCR test to sell via World Class companies like Bruker et al.Then first human Cancer trial doses.And loads of other collaborations with World Class companies (including stem cell research) who have repeatedly extended their collaborations with Avacta. Not forgetting Sanofi bought Ablynx for $4.8 billion in 2018 who were a company with a similar massive pipeline to Avct affimers.They paid $4.8 billion because Ablynx were at the Clinical Trials stage which explains why "Sir Al" has repeatedly said that this Cancer Trial news is a major milestone for Avct. It opens the doors for a big money bid. If you google it you will see that "Sir Al" himself has referred to the $4.8 billion buy out on several occasions but added that AVCT would need to be at the Clinical Stage.The $4.8 billion buy out didnt even include a Gold Standard LFT & PCR test for the biggest pandemic in the World for over 100 years.So how much for Avct when the bid finally arrives, which it surely will this year/next ? year.We WILL be being looked at by some seriously big companies with very deep pockets now, if we weren't already.
16/2/2021
16:05
viking24: I would expect quite positive news flow over the next two or three weeks, which could result in ground breaking impact on earnings, a re rating of the company and hence a share price at a whole new level. No10 is supporting rapid LFT use as soon as possible as the potential impact on the economy will be substantial and change the society.England has a leading position on the Vaccine side and will now have potentially a global leading position on the LFT testing area.The Diagnostic testing area is a fast growing place to be right now,M&A is picking up momentum and it is very clear Avacta will be there to provide rapid testing and the key issue which the testing companies will be facing is to be able to adapt to the any potential changes in the pandemic/variants.Great move in the share price, but surely the market need to re rate the company and look at what sort of growth potential we are looking at.
15/2/2021
14:06
roundhowe: A full on ramp....binary....either believe or don't. Simple really. Myles McNulty @MylesMcNulty · 56m ...for #AVCT's share price in the even of a successful LFT is MANY multiples of 100%. The R/R is just wrong, in my view. Of course, this does not account for #AVCT's other interests, both in the Diagnostics div and the Therapeutics div. Why the undervaluation? Besides a lack... 12/14 1 10 Myles McNulty @MylesMcNulty · 56m ...of understanding by many market participants of the size of the global market for at-home LFTs soon to materialise, I think #AVCT is being punished due to delays in product development, along with some questionable recent business decisions. All water under the bridge, 13/14 1 1 16 Myles McNulty @MylesMcNulty · 58m ...if the clinical data that is due before the end of next week is as we all hope it will be! I remain as optimistic as ever. The cashflows that the LFT will deliver will prove transformational for #AVCT's Therapeutic division too. And the potential there is even greater. 14/14
12/2/2021
08:42
lukead: Possibly coincidence but that Omega RNS helped the share price here and maybe guys now transferring from GDR, along with the much as anticipated positive news, the mix is giving the share price a lift
09/2/2021
23:04
grosstonnage: Why not compare AVCT share price performance with that of BPC.
Avacta share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AVCT
Avacta
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210227 10:59:17